Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
CAPR Capricor Therapeutics, Inc. daily Stock Chart
CAPR [NASD]
Capricor Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.84 Insider Own1.00% Shs Outstand8.37M Perf Week-1.12%
Market Cap14.81M Forward P/E- EPS next Y-1.60 Insider Trans0.00% Shs Float7.17M Perf Month68.57%
Income-9.40M PEG- EPS next Q-0.53 Inst Own5.20% Short Float0.38% Perf Quarter-31.40%
Sales1.40M P/S10.58 EPS this Y-669.10% Inst Trans126.40% Short Ratio0.17 Perf Half Y-62.82%
Book/sh0.95 P/B1.86 EPS next Y31.60% ROA-114.10% Target Price19.50 Perf Year-70.50%
Cash/sh0.81 P/C2.18 EPS next 5Y- ROE-264.00% 52W Range1.00 - 8.85 Perf YTD38.28%
Dividend- P/FCF- EPS past 5Y9.40% ROI-191.60% 52W High-80.00% Beta2.13
Dividend %- Quick Ratio7.60 Sales past 5Y27.10% Gross Margin- 52W Low77.00% ATR0.17
Employees18 Current Ratio7.60 Sales Q/Q-50.00% Oper. Margin- RSI (14)61.50 Volatility9.51% 11.19%
OptionableNo Debt/Eq0.94 EPS Q/Q68.30% Profit Margin- Rel Volume0.73 Prev Close1.77
ShortableYes LT Debt/Eq0.94 EarningsFeb 06 AMC Payout- Avg Volume156.91K Price1.77
Recom2.50 SMA2017.15% SMA5015.21% SMA200-41.55% Volume0 Change0.00%
Dec-26-18Downgrade Maxim Group Buy → Hold
Jan-26-18Reiterated H.C. Wainwright Buy $6.50 → $8.60
Sep-15-17Reiterated H.C. Wainwright Buy $2.15 → $6.50
Feb-13-17Resumed Rodman & Renshaw Buy $14
Jul-06-16Resumed H.C. Wainwright Buy $13
Jun-15-16Initiated ROTH Capital Buy
Dec-19-19 01:14PM  Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market GlobeNewswire -5.31%
Dec-17-19 01:52PM  Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market GlobeNewswire -5.45%
Dec-11-19 05:29AM  We're A Little Worried About Capricor Therapeutics's (NASDAQ:CAPR) Cash Burn Rate Simply Wall St.
Nov-07-19 05:15PM  Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:00PM  Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update GlobeNewswire
Nov-01-19 09:00AM  Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7 GlobeNewswire
Oct-27-19 09:16AM  How Capricor Therapeutics, Inc. (NASDAQ:CAPR) Can Impact Your Portfolio Volatility Simply Wall St.
Oct-21-19 09:25AM  Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD) GlobeNewswire
Oct-14-19 09:35AM  CHF Solutions System to be Used in JAHVH Study After Final Nod Zacks
Oct-07-19 12:27PM  A Look At Benzinga Pro's Most-Searched Tickers For October 7, 2019 Benzinga -10.42%
06:30AM  Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months GlobeNewswire
Oct-04-19 10:09AM  Zynex (ZYXI) Scales 52-Week High: What's Driving the Stock? Zacks
Oct-02-19 09:15AM  Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET GlobeNewswire
Oct-01-19 09:14AM  Abbott (ABT) Gets FDA Nod for Spinal Cord Stimulation System Zacks
Sep-26-19 11:24AM  Align Gains on Innovation Despite Poor Case Shipment in China Zacks
09:47AM  Natera (NTRA) Scales 52-Week High: What's Driving the Stock? Zacks
Sep-25-19 08:44AM  Illumina (ILMN) Inks Deal to Develop Distributable Test Kits Zacks
Sep-24-19 11:25AM  FDA Nods to Medtronic's (MDT) New Age Evolut PRO+ TAVR Zacks
09:20AM  Insulet Receives FDA Approval for ACE Pump Implementation Zacks
07:42AM  Capricor Therapeutics shares climb 3.6% on news FDA to meet to discuss DMD treatment MarketWatch
07:30AM  Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy GlobeNewswire
Sep-23-19 09:44AM  Bruker (BRKR) Enters Into Alliance With Murdoch University Zacks
Sep-21-19 08:20AM  Did You Manage To Avoid Capricor Therapeutics's (NASDAQ:CAPR) Devastating 92% Share Price Drop? Simply Wall St.
Sep-20-19 09:12AM  Neogen Forms Partnership With IGS to Enhance Beef Profile Zacks +8.42%
Sep-19-19 08:41AM  Medtronic Receives European Nod for Glucose Monitoring System Zacks
Sep-17-19 12:29PM  A Look At Benzinga Pro's Most-Searched Tickers For September 17, 2019 Benzinga +13.60%
08:38AM  Abbott Partners With Sanofi to Upgrade Diabetes Management Zacks
07:00AM  Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society GlobeNewswire
Sep-11-19 09:04AM  Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring Zacks
Sep-06-19 07:30AM  Capricor Therapeutics to Present at Upcoming Conferences GlobeNewswire +5.12%
Aug-23-19 08:37AM  Neogen Gets AOAC Validation for NeoSeek to Ensure Food Safety Zacks
Aug-22-19 07:31AM  NuVasive's New TLIF Implant Broadens Spine Surgery Option Zacks
Aug-20-19 09:03AM  Boston Scientific's (BSX) Vercise Gevia DBS Gets FDA Nod Zacks -8.03%
Aug-16-19 10:24AM  Here's What We Think About Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Pay Simply Wall St.
Aug-06-19 06:05PM  Capricor Therapeutics (CAPR) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:00PM  Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Aug-01-19 10:32AM  Will Capricor Therapeutics (CAPR) Report Negative Q2 Earnings? What You Should Know Zacks -9.55%
Jul-30-19 08:00AM  Capricor Therapeutics to Present Second Quarter 2019 Financial Results and Recent Corporate Update on August 6 GlobeNewswire
Jul-25-19 07:00AM  Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy GlobeNewswire +5.46%
Jul-17-19 07:00AM  Capricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy GlobeNewswire -5.00%
Jul-16-19 12:44PM  A Look At Benzinga Pro's Most-Searched Tickers For July 16, 2019 Benzinga
Jul-15-19 02:59PM  Capricor Therapeutics News: Why CAPR Stock Is Skyrocketing Today InvestorPlace +93.48%
08:45AM  Capicor Therapeutics' stock rockets on heavy volume after positive MD trial results MarketWatch
06:00AM  Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy GlobeNewswire
Jul-02-19 02:23PM  What Kind Of Shareholders Own Capricor Therapeutics, Inc. (NASDAQ:CAPR)? Simply Wall St.
May-13-19 05:15PM  Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:06PM  Capricor: 1Q Earnings Snapshot Associated Press
04:00PM  Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM  Capricor Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
May-06-19 04:00PM  Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13 GlobeNewswire
Apr-05-19 10:52AM  Will Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Earnings Grow In The Years Ahead? Simply Wall St.
Mar-28-19 04:25PM  Capricor: 4Q Earnings Snapshot Associated Press
04:00PM  Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-21-19 08:00AM  Capricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28 GlobeNewswire +6.07%
Feb-21-19 07:40AM  Capricor Therapeutics, Inc. (NASDAQ:CAPR): Commentary On Fundamentals Simply Wall St.
Feb-06-19 07:00AM  Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy GlobeNewswire
Jan-24-19 09:30AM  4 Healthcare Stocks Looking To Have A Strong Thursday (1/24/19) ACCESSWIRE -8.73%
07:00AM  Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricors Novel Cell Therapy GlobeNewswire
Jan-22-19 07:00AM  Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA GlobeNewswire
Jan-18-19 02:56PM  Does Capricor Therapeutics, Inc.s (NASDAQ:CAPR) CEO Pay Reflect Performance? Simply Wall St. +7.26%
Dec-27-18 07:25AM  Factors of Influence in 2019, Key Indicators and Opportunity within Halozyme Therapeutics, Capricor Therapeutics, Appian, Yext, Agile Therapeutics, and Corbus Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire -11.11%
Dec-26-18 06:58AM  U.S. drug developer Capricor places Duchenne drug trial on hold Reuters -20.02%
06:26AM  Capricor places Duchenne drug trial on hold Reuters
Dec-04-18 09:53AM  Could The Capricor Therapeutics Inc (NASDAQ:CAPR) Ownership Structure Tell Us Something Useful? Simply Wall St.
Nov-28-18 08:35AM  Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-13-18 05:15PM  Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:09PM  Capricor: 3Q Earnings Snapshot Associated Press
04:01PM  Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-12-18 07:00AM  Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial GlobeNewswire -5.06%
Nov-08-18 07:00AM  Capricor Therapeutics to Present Corporate Overview and Poster at Action Duchenne International Conference GlobeNewswire
Nov-07-18 10:30AM  Analysts Estimate Capricor Therapeutics (CAPR) to Report a Decline in Earnings: What to Look Out for Zacks
Nov-06-18 07:00AM  Capricor Therapeutics to Present Third Quarter Financial Results and Corporate Update on November 13 GlobeNewswire
Nov-02-18 07:00AM  Capricor Therapeutics to Provide Corporate Update at BIO-Europe Conference on Nov. 6 GlobeNewswire +10.31%
Oct-22-18 07:00AM  Capricor Therapeutics to Participate in Upcoming Conferences GlobeNewswire
Oct-20-18 10:30AM  Is Capricor Therapeutics Incs (NASDAQ:CAPR) 18% Better Than Average? Simply Wall St.
Oct-17-18 09:00AM  Market Trends Toward New Normal in Halozyme Therapeutics, Fitbit, Iconix Brand Group, Leap Therapeutics, LightPath Technologies, and Capricor Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Sep-14-18 08:41AM  S Spotlight On Capricor Therapeutics Incs (NASDAQ:CAPR) Fundamentals Simply Wall St.
Aug-23-18 07:50AM  New Research Coverage Highlights Live Nation Entertainment, LightPath Technologies, Synchronoss Technologies, Mallinckrodt public limited company, Capricor Therapeutics, and Mersana Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-21-18 07:00AM  Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles GlobeNewswire
Aug-09-18 05:15PM  Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:12PM  Capricor: 2Q Earnings Snapshot Associated Press
04:00PM  Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Aug-02-18 04:00PM  Capricor Therapeutics to Present Second Quarter Financial Results and Corporate Update on August 9 GlobeNewswire
Jul-17-18 08:56AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops GlobeNewswire
Jul-13-18 09:00AM  Capricor Therapeutics and PPMD to Host Webinar for Duchenne Muscular Dystrophy Community on July 18 GlobeNewswire +8.14%
Jun-28-18 07:00AM  Capricor Therapeutics to Present at PPMD Annual Conference GlobeNewswire
Jun-20-18 12:05PM  Should You Be Holding Capricor Therapeutics Inc (NASDAQ:CAPR)? Simply Wall St.
Jun-13-18 07:35AM  Detailed Research: Economic Perspectives on CarGurus, ArcelorMittal, Capricor Therapeutics, B&G Foods, Ionis Pharmaceuticals, and Photronics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jun-01-18 04:34PM  Does Capricor Therapeutics Incs (NASDAQ:CAPR) PE Ratio Warrant A Buy? Simply Wall St.
May-29-18 07:00AM  Capricor Therapeutics to Present at the 2018 BIO International Convention in Boston GlobeNewswire
May-15-18 08:03PM  How Did Capricor Therapeutics Incs (NASDAQ:CAPR) 23.03% ROE Fare Against The Industry? Simply Wall St.
May-10-18 04:36PM  Capricor: 1Q Earnings Snapshot Associated Press
04:00PM  Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-04-18 08:00AM  Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10 GlobeNewswire
May-03-18 07:00AM  Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal GlobeNewswire
Apr-30-18 07:00AM  Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy GlobeNewswire
Apr-23-18 07:40AM  Wired News Capricors New Pre-Clinical Study Establishes that Repeated Doses of CAP-1002 Lead to Enhanced Exercise Capacity in a Disease Model of Duchenne Muscular Dystrophy ACCESSWIRE
Apr-19-18 07:00AM  Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model GlobeNewswire
Apr-12-18 07:00AM  Capricor to Provide Presentation at the Alliance for Regenerative Medicines Investor Day GlobeNewswire +11.94%
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002 that completed phase I/II clinical trial in subjects with DMD; phase I clinical trial for treating heart failure; and phase I/II clinical trial in subjects with myocardial infarction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.
open in yahoo | open in reuters | open in google